ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1369

Adipose Tissue-Derived Stromal Vascular Fraction Plus Fat Grafts for Hand Therapy in Patients with Systemic Sclerosis. a Randomized Controlled Clinical Trial

Martín Iglesias1, Iván Torre-Villalvazo1, Armando Tovar-Palacio1, Alejandro Zentella-Dehesa1, Patricia Butrón-Gandarillas1, Marta Durand-Carbajal1, Erik Torre-Anaya2, Martha Guevara2 and Tatiana Rodriguez-Reyna2, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

Meeting: ACR Convergence 2021

Keywords: digital ulcers, joint contractures, Mesenchymal stem cells, Scleroderma, Systemic, vasculopathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Adipose tissue-derived Stromal Vascular Fraction (ADSVF) has been proposed as regenerative treatment for hand deformities and digital ulcer healing in patients with Systemic Sclerosis (SSc). We aimed to evaluate its regenerative properties after local injection of autologous ADSVF in the hands of these patients.

Methods: This was an open-label, monocentric, randomized controlled study, approved by our local IRB and registered at clinicaltrials.gov (NCT04387825). Twenty patients diagnosed with SSc and moderate to severe hand contractures according to the Medsger’s severity scale and/or digital tip ischemic ulcers (distal to PIP joints) with more than 30 days of evolution despite medical treatment, were enrolled and assigned to the experimental or control group. Both groups continued standard medical treatment. Autologous ADSVF was obtained by liposuction and then by enzymatic digestion in the experimental group. This group received ADSVF plus fat micrografts injection into the right hand. Digital oximetry, pain, Raynaud phenomenon (RP), digital ulcer healing (DUH) time, range of motion (ROM), vascular density of the nail bed, cell surface markers, hand function, and quality of life scores were evaluated in both groups. The follow-up period was 168 days. Continuous variables were expressed as median with 95% confidence intervals. The differences between before and after the intervention were analyzed with the Wilcoxon range test, and the differences between the control and experimental groups at 0 and 168 days were analyzed with the Mann–Whitney U test. The range of total viable nucleated cells in the ADSVF was 167.5×106 , with viability of 82% or higher. Stem cell markers into the ADSVF were: CD34+ 4.72% , CD45+ 43.9%, CD44+ 36.3%, CD73+ 6.18 %, CD90+ 34.4 %, CD105+ 7.27%, HLA-DR 12.1%, Stromal cells 4.05%.

Results: At 168 days of follow-up there were significant improvements in pain level (p= 0.02) and DUH (p= 0.003) only in the experimental group. We also found increased active ROM of the MCP joints in the treated hand of the experimental group, while the non-treated hand MCP joint ROM decreased significantly. Raynaud phenomenon improved in both groups. There were no changes in disease activity or severity, nailfold capillaroscopy pattern, mobility or hand function between both treatment groups. One patient in the experimental group reported transient hand edema that solved within 7 days.

Conclusion: ADSVF local injection is safe and well tolerated in SSc patients. This therapeutic method may improve pain and time to digital ulcer healing in patients with severe joint contractures and refractory digital ulcers.


Disclosures: M. Iglesias, None; I. Torre-Villalvazo, None; A. Tovar-Palacio, None; A. Zentella-Dehesa, None; P. Butrón-Gandarillas, None; M. Durand-Carbajal, None; E. Torre-Anaya, None; M. Guevara, None; T. Rodriguez-Reyna, None.

To cite this abstract in AMA style:

Iglesias M, Torre-Villalvazo I, Tovar-Palacio A, Zentella-Dehesa A, Butrón-Gandarillas P, Durand-Carbajal M, Torre-Anaya E, Guevara M, Rodriguez-Reyna T. Adipose Tissue-Derived Stromal Vascular Fraction Plus Fat Grafts for Hand Therapy in Patients with Systemic Sclerosis. a Randomized Controlled Clinical Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/adipose-tissue-derived-stromal-vascular-fraction-plus-fat-grafts-for-hand-therapy-in-patients-with-systemic-sclerosis-a-randomized-controlled-clinical-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adipose-tissue-derived-stromal-vascular-fraction-plus-fat-grafts-for-hand-therapy-in-patients-with-systemic-sclerosis-a-randomized-controlled-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology